TG Therapeutics price to sales ratio TGTX

Market value divided by revenue over the last twelve months, since 2022.

Today, Oct 23, 2026: 10.4×
5-year median: 12.1×
Against its 5-year history: 31st; percentile: 0 is its lowest day, 100 its highest
5-year range: 7.2× to 198×
Peer median: 5.8×

TG Therapeutics' price to sales ratio is 10.4× as of Oct 23, 2026.

That is below its 5-year median of 12.1×, lower than on 69% of days in the last 5 years.

Over that time it ranged from 7.2× in Mar 2026 to 198× in Apr 2022.

The median for 10 large drugmakers of a similar size is 5.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	10.4×	7.2×	12.5×
2025	9.2×	9.2×	20.7×
2024	19.1×	8.5×	20.6×
2023	13.6×	8.2×	187×
2022	122×	73.8×	198×

Against its peers

Companies in Drug Manufacturers - General nearest TG Therapeutics' size, closest first, today.

Company	Price to sales ratio
TGTXTG Therapeutics	10.4×
PTGXProtagonist Therapeutics	31.8×
CORTCorcept Therapeutics	11.2×
ALKSAlkermes plc.	4.4×
AMRXAmneal Pharmaceuticals	2.1×
BMRNBiomarin Pharmaceutical	3.2×
LGNDLigand Pharmaceuticals	20.8×
KNSAKiniksa Pharmaceuticals International	7.1×
JAZZJazz Pharmaceuticals	3.0×
INDVIndivior Pharmaceuticals	3.1×
ARQTArcutis Biotherapeutics	8.5×
Peer median	5.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on TG Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.